Market+ (iPhone)

Market+ (Android)

US STOCKS

FUNDS

FX & CRYPTO

SH/SZ-HK

HK STOCKS

IPO Plus - IPO

To-be Listed

	Name▼ / Code▼	Industry	Offer Price	Lot Size	Entry Fee	Closing Date	Grey Market Date▼	Listing Date▲
	Herbs Generation 02593.HK	Health Care Supplies	3.75-4.15	800	3,353	2024/12/16	2024/12/18	2024/12/19
	Xiaocaiyuan 00999.HK	N/A	8.5	800	N/A	2024/12/17	Data is not available	2024/12/20

Summary

We are a China-based medical device company dedicated to the development of interventional products for the treatment of structural heart diseases. Our Company was established in the PRC in November 2011. Since then we have developed a series of treatment solutions targeting different types of structural heart diseases, including tricuspid valve diseases, aortic valve diseases, mitral valve diseases and heart failure. LuX-Valve, our Core Product and our proprietary first-generation transcatheter tricuspid valve replacement (“TTVR”) system, is designed for patients with both severe tricuspid regurgitation and high surgical risk. Ken-Valve, our another Core Product, is designed for the treatment of severe aortic regurgitation (or combined with aortic stenosis), and is expected to address the needs of a larger patient pool than those transcatheter aortic valve replacement (“TAVR”) systems that are indicated for the treatment of aortic stenosis alone. TAVR market is a relatively mature market with many commercialized products, including 25 major TAVR products approved for commercialization globally and nine TAVR products approved for commercialization in China as of the Latest Practicable Date, according to Frost & Sullivan. We are also developing eight other product candidates featuring advanced technologies, targeting different types of valvular diseases and heart failure. WE CANNOT GUARANTEE THAT WE WILL ULTIMATELY DEVELOP OR MARKET OUR CORE PRODUCTS SUCCESSFULLY. Primarily driven by population aging, structural heart diseases are becoming increasingly prevalent both in China and worldwide. Among all structural heart diseases, valvular heart diseases are the most prevalent. According to Frost & Sullivan, approximately 221.4 million patients worldwide, including approximately 37.5 million patients in China, suffered from valvular heart diseases in 2021. Despite the high prevalence, there were few safe and effective treatments for structural heart diseases. To capitalize on this market opportunity and to fulfill the unmet medical needs of patients with structural heart diseases, we have developed a broad product pipeline that covers various structural heart diseases. Source: Jenscare-B (09877) Prospectus (IPO Date : 2022/09/23)
Listing Market	MAIN
Industry	Biotechnology - Medical Devices
Background	H Shares
Major Business Area	N/A

Corporate Information

Substantial Shareholders	LV Shiwen & Associates (Total share: 24.19%); (H share: 22.02%) Li Hui & Associates (Total share: 13.50%); (H share: 14.35%) PAN Fei & Associates (Total share: 11.94%); (H share: 10.78%) Trident Trust Company (HK) Limited (Total share: 5.68%); (H share: 7.64%) Hillhouse Investment Management, Ltd. (Total share: 5.21%); (H share: 3.50%)
Directors	LV Shiwen (Chairman and Chief Executive Officer and Chief Technology Officer and Executive Director) PAN Fei (Vice President and Chief Financial Officer and Executive Director) CHEN Xinxing (Non-Executive Director) TAN Ching (Non-Executive Director) XIE Youpei (Non-Executive Director) ZHENG Jiaqi (Non-Executive Director) DU Jiliu (Independent Non-Executive Director) LIN Shoukang (Independent Non-Executive Director) MEI Lehe (Independent Non-Executive Director)
Company Secretary	LI Yuanyuan WONG Wai Chiu
Principal Bankers	Agricultural Bank of China Limited Bank of Ningbo
Solicitors	Commerce & Finance Law Offices O Melveny & Myers LLP
Auditors	Ernst & Young
Registered Office	40th Floor, Dah Sing Financial Centre, No.248 Queen’s Road East, Wanchai, Hong Kong
Share Registrars	Computershare Hong Kong Investor Services Ltd. [Tel: (852) 2862-8628]
Share Registrars Tel No	(852) 2862-8628
Internet Address	http://www.jenscare.com
Email Address	[email protected]
Tel No	(86 574) 6393-5666
Fax No

SITEMAP

AASTOCKS.com

Members

Forgot Password

About Us

Email: [email protected]

AASTOCKS.COM LIMITED (阿斯達克網絡信息有限公司) All rights reserved.

Disclaimer

You expressly agree that the use of this app/website is at your sole risk.

AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co. Ltd, Nasdaq, Inc., their respective holding companies and/or any subsidiaries of such holding companies, their Sources and/or other third party data provider(s) endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

Neither AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co.Ltd., Nasdaq, Inc. nor their respective holding companies and/or any subsidiaries of such holding companies nor their Sources and/or other third party data provider(s) make any express or implied offers, representations or warranties (including, without limitation, any warranty or merchantability or fitness for a particular purpose or use) regarding the Information.

Neither AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co. Ltd., Nasdaq, Inc. nor their respective holding companies and/or any subsidiaries of such holding companies nor their Sources and/or other third party data provider(s) will be liable to any Subscriber or any other party for any interruption, inaccuracy, error, or omission, regardless of cause, in the Information or for any damages (whether direct or indirect, consequential, punitive, or exemplary) resulting from its use by any party.

AASTOCKS.com Limited shall not be liable for any failure or delay in performance of its obligations under this Disclaimer because of circumstances beyond its reasonable control, including but without limitation, acts of God, typhoons, rainstorms, other natural disasters, government restrictions, strikes, wars, virus outbreak, network failures or telecommunications failures.

Morningstar Disclaimer: Copyright © 2020 Morningstar, Inc. All Rights Reserved. The information, data, analyses and opinions ("Information") contained herein: (1) include the proprietary information of Morningstar and Morningstar’s third party licensors; (2) may not be copied or redistributed except as specifically authorised; (3) do not constitute investment advice; (4) are provided solely for informational purposes; and (5) are not warranted to be complete, accurate or timely. Morningstar is not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.

The information and contents contained in this app/website are based on the analyses and interpretations of publicly available information obtained from sources believed to be reliable. Such analyses and information have not been independently verified and AASTOCKS.com Limited makes no guarantees to their accuracy, completeness, timeliness or correctness.

The information, financial market data, quotes, charts, statistics, exchange rate, news, research, analysis, buy and sell ratings, Education Center and other information on this app/website should be used as references only at your own discretion. Prior to the execution of a security or any other trade based upon the Information, you are advised to consult independent professional advice to verify pricing information or to obtain more detailed market information. AASTOCKS.com Limited is not soliciting any subscriber or app/website visitor to execute any trade. Any trades executed following the said information, commentaries and/or buy/sell ratings on this app/website are taken at your own risk for your own account.

AASTOCKS.com Limited provides the information and services on an "AS IS" basis. The information and contents on this app/website are subject to change without notice. AASTOCKS.com Limited reserves the right, in its sole discretion but without any obligation, to make improvements to, or correct any error or omissions in any portion of this app/website at any time.

The subscriber or app/website visitor agrees not to reproduce, retransmit, disseminate, distribute, broadcast, publish, circulate, sell or commercially exploit the information and contents on this app/website in any manner without the express written consent of AASTOCKS.com Limited.

Investment involves risk. You may make use of the Education Center of this website for academic reference purposes at your own discretion. AASTOCKS.com Limited cannot and does not give any assurance that the present or future buy/sell commentaries and signals on this app/website will be profitable. AASTOCKS.com Limited cannot guarantee, and the subscriber or app/website visitor should not assume, that the future performance will equal past performance.

AASTOCKS.com Limited may point to other sites that may be of interest to the subscriber or app/website visitor but for which AASTOCKS.com Limited has no responsibility and only provides this as a service to the subscriber or app/website visitor.

AASTOCKS.com Limited does not represent or endorse the accuracy or reliability of any information, advertisements or contents contained on, distributed through, or linked, downloaded or accessed from any of the services on this app/website. AASTOCKS.com Limited cannot and does not guarantee the quality or reliability of any products or information purchased or obtained by you as a result of an advertisement or any other information displayed on this app/website.

AATV is a video platform owned by AASTOCKS.com Limited.

You acknowledge that: (i) AATV is provided for information purposes only and, in particular, is not intended for trading purposes; (ii) AATV does not and none of the information contained in its program constitutes a solicitation, offer, opinion, or recommendation by us to buy or sell any security, or to provide legal, tax, accounting, or investment advice or services whether or not regarding the profitability or suitability of any security or investment; and (iii) AATV is not intended for use by, or distribution to, any person or entity in any jurisdiction or country where such use or distribution would be contrary to law or regulation.

The financial analysis or opinion expressed in the AATV programs is for reference and discussion only, and does not represent AASTOCKS.com Limited. Investors must make their own investment decisions based on their own investment objectives and financial situation. AASTOCKS.com Limited shall not, directly or indirectly, be liable, in any way, to you or any other person for any: (i) inaccuracies or errors in or omissions from AATV including, but not limited to, quotes and financial data; (ii) delays, errors, or interruptions in the transmission or delivery of AATV; or (iii) loss or damage arising therefrom or occasioned thereby, or by any reason of nonperformance.

AASTOCKS.com Limited reserves the right to change this Disclaimer at any time by posting changes online at this app/website. You are responsible for reviewing regularly information posted therein to obtain timely notice of such changes. Your continued use of this app / website after changes are posted constitutes your acceptance of this Agreement as modified by the posted changes.

The disclaimer herein shall be governed by the law of the Hong Kong Special Administrative Region of the People's Republic of China ("Hong Kong") and you agree to submit to the exclusive jurisdiction of the Hong Kong courts.

In the event of any discrepancy between the Chinese and English versions, the English version shall prevail.

Last updated on 6 January 2023.